Friday August 23, 2019 0 comments
“We chose to join Catalyst because of the concentration of medical expertise and the ability to meet and share ideas with both startups and mature companies in the industry,” said Alan Sage, Vaporox CEO.
“It is so great to be surrounded by so many other driven people developing products to improve patient lives.”
Vaporox has developed a patented and FDA-cleared technology called Vaporous Hyperoxia Therapy (VHT™), which accelerates the healing of 9 different types of wounds.
For example, chronic diabetic foot ulcers (DFUs), which are both painful and debilitating, generate annual healthcare costs around $15 billion/year in the U.S. alone. DFUs are the leading cause of non-traumatic lower extremity amputations in the U.S.
In a completed clinical trial, VHT achieved almost 3 times the healing of standard wound care.
“Deploying VHT nationally could cut healthcare costs by $10 billion/year and prevent almost 100,000 amputations annually,” said Sage.
VHT works by encapsulating the limb in a chamber where an ultrasonic vapor of water and ionic silver is introduced to fight infection and bring moisture to the wound.
This is followed by applying pure oxygen at slight positive pressure. The ionic silver anti-microbial suppresses “bio-burden,” while the aqueous mist and the oxygen reproduce the conditions that would exist with healthy blood circulation, thus enabling the body to heal itself.
“At Catalyst, I see many medical device companies making a big impact on the lives of patients with debilitating conditions like diabetes,” said Catalyst HTI’s president Mike Biselli.
“Having the Vaporox team on campus is a shining example of the amazing technologies being built in Colorado and the companies that call our building home.”
Vaporox said it is actively raising a $1.53 million series seed round.